Back to Interventions
Substance / Medication

Choriogonadotropin

SNOMED 408755005UMLS C0018062

Overview

Active Ingredient
chorionic gonadotropin
RxNorm CUI
4986

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Female infertility
Hypogonadism
Undescended testicle

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Thyrotropin

LOINC 3016-3

secondary

Estradiol

LOINC 2243-4

primary

Testosterone

LOINC 2986-8

primary

Clinical Trials

54 trials linked to this intervention

54
Total Trials
7
Recruiting
16
With Results

Recent Trials

TRADE-Testosterone Replacement and Dutasteride Effectiveness

NCT00194675Phase 4Completed53 enrolled

Testosterone Replacement in Older Men and Atherosclerosis Progression

NCT00287586Phase 4Completed308 enrolled

Testosterone for Men With Insulin Treated Type 2 Diabetes

NCT00349362Phase 4Completed40 enrolled

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

NCT00350701Phase 4Completed49 enrolled

The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction

NCT00421460Phase 4Completed30 enrolled
View all 54 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Association of luteinizing hormone/choriogonadotropin receptor gene polymorphisms with polycystic ovary syndrome risk: a meta-analysis.
Zou Ju, Wu Daichao, Liu Yan et al. · Gynecol Endocrinol · 2019
PMID: 30182769Meta-Analysis
Differences between lutropin-mediated and choriogonadotropin-mediated receptor activation.
Grzesik Paul, Teichmann Anke, Furkert Jens et al. · FEBS J · 2014
PMID: 24438591Observational
Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS-LED trial).
Cramer Steven C, Hill Michael D, [object Object] · Int J Stroke · 2014
PMID: 24588854Observational
Seven non-contiguous intracellular residues of the lutropin/choriogonadotropin receptor dictate the rate of agonist-induced internalization and its sensitivity to non-visual arrestins.
Nakamura K, Liu X, Ascoli M · J Biol Chem · 2000
PMID: 10617611Observational
Cosegregation of a novel mutation in the sixth transmembrane segment of the luteinizing/choriogonadotropin hormone receptor with two Brazilian siblings with severe testotoxicosis.
Siviero-Miachon Adriana A, Kizys Marina M L, Ribeiro Manuela M et al. · Endocr Res · 2017
PMID: 27532428Case Report
Inherited mutation of the luteinizing hormone/choriogonadotropin receptor (LHCGR) in empty follicle syndrome.
Yariz Kemal O, Walsh Tom, Uzak Asli et al. · Fertil Steril · 2011
PMID: 21683950Case ReportFull text (PMC)
Novel C617Y mutation in the 7th transmembrane segment of luteinizing hormone/choriogonadotropin receptor in a Japanese boy with peripheral precocious puberty.
Nagasaki Keisuke, Katsumata Noriyuki, Ogawa Yohei et al. · Endocr J · 2010
PMID: 21060208Case Report
The N-Linked Glycosylation Site N201 in eel Lutropin/Choriogonadotropin Receptor Is Uniquely Indispensable for cAMP Responsiveness and Receptor Surface Loss, but Not pERK1/2 Activity.
Byambaragchaa Munkhzaya, Kim Dong-Wan, Park Sei Hyen et al. · Curr Issues Mol Biol · 2025
PMID: 40699744OtherFull text (PMC)
Functional Divergence for N-Linked Glycosylation Sites in Equine Lutropin/Choriogonadotropin Receptors.
Byambaragchaa Munkhzaya, Kang Han-Ju, Park Sei Hyen et al. · Curr Issues Mol Biol · 2025
PMID: 40864744OtherFull text (PMC)
Widespread Distribution of Luteinizing Hormone/Choriogonadotropin Receptor in Human Juvenile Angiofibroma: Implications for a Sex-Specific Nasal Tumor.
Wemmert Silke, Pyrski Martina, Pillong Lukas et al. · Cells · 2024
PMID: 39056799OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Endocrinology, Diabetes & Metabolism Physician

Internal Medicine — Endocrinology, Diabetes & Metabolism

NUCC 207RE0101X
Obstetrics & Gynecology Physician

Obstetrics & Gynecology

NUCC 207V00000X
Reproductive Endocrinology Physician

Obstetrics & Gynecology — Reproductive Endocrinology

NUCC 207VE0102X
Urology Physician

Urology

NUCC 208800000X
Find a Provider

Health Goals

Goals connected through associated conditions

Balance HormonesSupport Reproductive Health

Quick Facts

Type
Substance / Medication
Fully Specified Name
Choriogonadotropin (substance)
SNOMED CT
408755005
UMLS CUI
C0018062
RxNorm CUI
4986

Clinical Data

This intervention maps to 12 entities in the Ltrl knowledge graph.

3
Conditions
3
Biomarkers
4
Specialists
0
Symptoms
54
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.